EAU 2025 | What are the benefits of focal therapy in prostate cancer?

Nikhil Mayor • 4 Mar 2025

EAU 2025

Nikhil Mayor, MD, Imperial College London, London, UK, comments on the benefits of focal therapy in prostate cancer treatment, highlighting its potential to minimize impact on key functional outcomes such as erectile dysfunction and incontinence. The medium to long-term outcomes between focal therapy and radical therapy are equivalent, with similar 5-10 year life expectancy rates. However, longer-term data, beyond 10 years, are still being accrued and are expected to be reported in the coming years. This interview took place at the 2025 European Association of Urology (EAU) Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.